Compare NBHC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | DAWN |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2011 | 2021 |
| Metric | NBHC | DAWN |
|---|---|---|
| Price | $43.30 | $21.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $47.67 | $24.43 |
| AVG Volume (30 Days) | 309.3K | ★ 1.4M |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | $47,100,000.00 | ★ $158,182,000.00 |
| Revenue This Year | $39.96 | $55.03 |
| Revenue Next Year | $7.14 | $28.12 |
| P/E Ratio | $15.19 | ★ N/A |
| Revenue Growth | 2.86 | ★ 20.60 |
| 52 Week Low | $35.06 | $5.64 |
| 52 Week High | $43.42 | $21.53 |
| Indicator | NBHC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 66.59 | 80.29 |
| Support Level | $37.43 | $10.30 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.78 | 0.03 |
| MACD | 0.16 | -0.28 |
| Stochastic Oscillator | 82.64 | 90.91 |
National Bank Holdings Corp offers a full range of banking products and financial services to commercial, business, and consumer clients predominantly in Colorado, with a focus on personalized service through relationship managers and banking center associates. The company provides commercial and industrial loans, non-owner occupied commercial real estate loans, Small Business Administration loans as a Preferred Lender Provider, U.S. Department of Agriculture and Farm Service Agency loans, commercial deposit and treasury management products, business online and mobile banking, consumer and residential real estate loans, deposit services, and trust and wealth management services. Its services emphasize full-relationship banking, integrating lending, deposits, and cash management solutions.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.